BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Quest Diagnostics is Thursday's IBD Stock Of The Day. Shares are lingering in a buy zone, helped by a Texas court's ruling.

This was the stock's second consecutive day of losses.

Redburn Atlantic analyst Jamie Clark initiated coverage of Quest Diagnostics (DGX) with a Buy rating and $195 price target Don't Miss Our End ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Diving into Analyst Ratings: An In-Depth Exploration The analysis of recent analyst actions sheds light on the perception of Quest Diagnostics by financial experts. The following summary presents ...

There was a mix-up regarding my appointment for blood testing this morning. I arrived on time for my appointment but the kiosk indicated no appointment scheduled. It was 10 minutes to 12 (office ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Stay informed and make data-driven decisions with our Ratings Table. Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company ...